Actively Recruiting

Phase Not Applicable
Age: 21Years - 75Years
All Genders
NCT06764069

Feasibility Study to Evaluate an Intravascular Blood Continuous Glucose Sensor

Led by Glucotrack · Updated on 2025-01-08

10

Participants Needed

1

Research Sites

11 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this early first in man clinical trial is to evaluate the safety of an implantable continuous blood glucose monitoring system in participants with Diabetes Mellitus. Safety will be assessed by looking at the absence of procedure or device related adverse events. Additionally, the surgical procedure and device performance will be evaluated. Key Research Questions: 1. Were there any adverse events associated with the insertion of the Sensor Lead? 2. Did Participants experience any device-related adverse events from the Sensor Lead insertion through the 96-hour observation period and subsequent removal of the Sensor Lead? 3. How effectively did the device capture data during the 96-hour wear period?

CONDITIONS

Official Title

Feasibility Study to Evaluate an Intravascular Blood Continuous Glucose Sensor

Who Can Participate

Age: 21Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 21 to 75 years old inclusive
  • Generally in good health as determined by the investigator
  • Clinical diagnosis of type 1 or type 2 diabetes verified by medical records
  • Using intensive insulin therapy with 3 or more injections per day or continuous insulin infusion
  • HbA1c less than 9.0% within the last 3 months
  • Adequate venous access as assessed by medical staff
  • Willing to comply with study procedures and be admitted to hospital for up to 5 days
  • Willing to perform up to 7 blood glucose fingerstick tests daily using provided meters and strips
  • Willing to wear a subcutaneous continuous glucose sensor during the study
  • Willing to always carry a study-provided Android phone during the study
  • Access to internet for periodic uploads of study device data
  • Body mass index between 18 and 35 kg/m2
  • Able to understand and comply with study procedures and provide informed consent in English or via translator
Not Eligible

You will not qualify if you...

  • Currently taking acetaminophen and unable to switch to another anti-inflammatory or pain reliever
  • Currently treated with anticoagulation medication
  • History of deep vein thrombosis, pulmonary embolism, or blood clotting disorder that may affect safety
  • Currently using non-insulin glucose-lowering agents SGLT2 or insulin secretagogues
  • Female of childbearing potential with a positive pregnancy test
  • Female of childbearing potential planning pregnancy or not using reliable contraception
  • One or more episodes of hypoglycemia or diabetic ketoacidosis requiring medical care or assistance in the last 6 months
  • Hematocrit lower than normal reference range
  • Known clinically relevant cardiovascular disease
  • Current or recent use of systemic corticosteroids or unstable thyroid hormone treatment
  • History of alcoholism or drug abuse that may affect safety or study participation
  • Significant acute or chronic illness that may interfere with safety or study results
  • Currently participating in another clinical drug or device study
  • Study staff members performing this study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Instituto do Coração (InCor) |

São Paulo, Brazil, Brazil, 05403-000

Actively Recruiting

Loading map...

Research Team

S

Sandra L Martha

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here